Drug intelligence / Profile preview

SCG-162

Development stage: Preclinical
Lead developer: SCG Cell Therapy
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

SCG-162 is an investigational T cell receptor (TCR) therapy developed by SCG Cell Therapy. It targets Epstein-Barr Virus (EBV) proteins and acts as an EBV protein inhibitor. The primary indication under investigation is nasopharyngeal carcinoma, a cancer often associated with EBV infection. As of the latest update, its highest development phase is preclinical. The drug’s mechanism involves engineered T cells designed to recognize and attack cells expressing EBV proteins, aiming to harness the immune system for targeted cancer therapy[1][2].

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on SCG-162.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCG-162.

Explore the full profile